Biotechnology ASX Stock News and Announcements

18 November 2024

New!
2024 Chairman Address and AGM Presentation

Paradigm Biopharmaceuticals outlines progress in clinical trials and strategic partnerships.

Paradigm Biopharmaceuticals Clinical Trials Osteoarthritis Biopharma Stock Market News

Posted on: 18/11/2024

Read More

17 November 2024

New!
RAD 301 shows strong imaging potential in pancreatic cancer

Radiopharm announces promising imaging results for pancreatic cancer using 68Ga-RAD 301.

Radiopharm Theranostics Pancreatic Cancer Radiopharmaceuticals Stock Market News

Posted on: 17/11/2024

Read More

14 November 2024

New!
Successful Placement of $660k and Share Purchase Plan

Anatara Lifesciences raises $1.16 million for IBS and anti-obesity projects.

Anatara Lifesciences IBS Treatment Stock Market News Biotechnology Clinical Trials

Posted on: 14/11/2024

Read More
New!
Opthea Received A$15.9 Million R&D Tax Incentive

Opthea receives A$15.9 million for R&D, enhancing cash reserves.

Opthea Biopharmaceuticals R&D Tax Incentive Stock Market News Clinical Trials

Posted on: 14/11/2024

Read More
New!
Chair's Address to Shareholders

Opthea reports progress in wet AMD trials and leadership transitions.

Opthea Wet AMD Clinical Trials Biotechnology Leadership Changes

Posted on: 14/11/2024

Read More

12 November 2024

Trading Halt

Anatara Lifesciences halts trading pending a capital raising announcement.

Anatara Lifesciences Capital Raising Trading Halt Stock Market News

Posted on: 12/11/2024

Read More
Pause in Trading

Anatara Lifesciences pauses trading pending further announcement.

Anatara Lifesciences Trading Halt Stock Market News Biotechnology

Posted on: 12/11/2024

Read More

31 October 2024

Appendix 4C & Q1 FY25 Activities Report

Anatara Lifesciences progresses GaRP-IBS trial and secures European patent.

Anatara Lifesciences GaRP-IBS Trial European Patent Stock Market News Biotechnology

Posted on: 31/10/2024

Read More

18 September 2024

Opthea Announces Completion of Drug Substance Campaign

Opthea finalizes drug substance PPQ campaign for sozinibercept.

Opthea Sozinibercept Biopharmaceutical Wet AMD Stock Market News

Posted on: 18/09/2024

Read More

17 September 2024

PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3

FDA confirms safety and tolerability of Paradigm's OA treatment, paving the way for Phase 3 trial.

Paradigm Biopharmaceuticals FDA Approval Clinical Trials Osteoarthritis Treatment Stock Market News

Posted on: 17/09/2024

Read More

31 July 2024

Quarterly Activities/Appendix 4C Cash Flow Report

Cambium Bio announces merger completion and updates on Elate Ocular® Phase 3 trials.

Cambium Bio Regenerative Medicine Stock Market News Clinical Trials Biotechnology

Posted on: 31/07/2024

Read More
Quarterly Activities/Appendix 4C Cash Flow Report

Opthea completes pivotal trial enrolment and raises A$227.3m for wet AMD drug development.

Opthea Wet AMD Clinical Trials Biopharmaceutical Stock Market News

Posted on: 31/07/2024

Read More

22 July 2024

FDA IND approval for Phase 2b trial in brain metastases

Radiopharm Theranostics gains FDA approval for Phase 2b brain metastases imaging trial.

Radiopharm Theranostics FDA Approval Brain Metastases Stock Market News Biopharmaceutical

Posted on: 22/07/2024

Read More